Clinical Trial Update: Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating pembrolizumab in combination with vorinostat for patients with stage IV non-small cell lung cancer, with results posted in May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Zolinza (vorinostat)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Lung Cancer, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-04